f. MDS with at least one of the following poor-risk features i. Poor-risk cytogenetics ii Int-2 or high IPSS score iii Treatment-related MDS iv MDS diagnosed before age 21 years v. Progression on or lack of response to standard hypomethylator therapy vi Life-threatening cytopenias 